The DEA has moved to schedule 7-OH, a concentrated kratom derivative with opioid-strength effects, setting up a wave of dependence and supply disruption for SUD providers.
Key Takeaways
- A legal product is about to become a Schedule I drug: The DEA moved on July 1, 2026 to temporarily schedule concentrated 7-OH and three synthetic relatives, the same class as heroin. The action targets enhanced products, not natural kratom leaf.
- Users did not think they were taking an opioid: 7-OH acts on the same receptor as morphine and heroin, but it has been sold as tablets, gummies, and shots marketed as plant-based supplements. Many people developed dependence without knowing what they had.
- The harm signal is already visible: Poison-center data from one center alone show hospitalizations tied to these products rising more than tenfold in a decade. Reported dependence and withdrawal cases climbed sharply heading into the ban.
- A ban creates a treatment problem: Prohibition will push existing users toward withdrawal and treatment, and may steer some to the illicit opioid supply. Providers should prepare for 7-OH dependence as a distinct clinical presentation.
The product sat by the register, next to the energy shots and the phone chargers, in a bright foil packet that looked like a supplement and was sold like one. It had a botanical-sounding name and a plant on the label; it was legal in most of the country, and a clerk would ring it up without a second glance. What it contained was a compound that binds the same receptor in the brain as morphine and heroin, at a concentration that occurs nowhere in nature, and a meaningful number of the people who started taking it for energy or pain or to take the edge off found, weeks later, that stopping produced the sweats and chills and clawing anxiety of opioid withdrawal. They had become dependent on an opioid without ever believing they had touched one.
That compound is 7-hydroxymitragynine, universally shortened to 7-OH, and in July the federal government began the process of making it illegal. The DEA announced its intent to place concentrated 7-OH and several synthetic relatives into Schedule I, the most restrictive tier of the Controlled Substances Act, alongside heroin and LSD. For the substance use disorder field, the scheduling is less an endpoint than a beginning, because banning a substance that a great many people are already dependent on does not make the dependence disappear. It relocates it into withdrawal, into treatment, and potentially into the illicit market, and the providers who treat opioid addiction should expect 7-OH to arrive in their waiting rooms.
What 7-OH Is and How It Reached Store Shelves
This story starts with kratom, the leaf of a Southeast Asian tree that has been used for generations as a mild stimulant and folk remedy and that occupies a contested but largely legal place in the American supplement market. Natural kratom leaf contains dozens of alkaloids, and 7-OH is one of them, present in only trace amounts. In the leaf, it is a minor component of a complex plant. What reached American store shelves over the past few years was something categorically different: products engineered to concentrate 7-OH far above any natural level, either extracted and enriched or synthesized outright, pressed into tablets and dissolvable shots and gummies that deliver a potent, direct hit of a nearly pure opioid agonist.
This is the distinction at the center of the regulatory action, and it matters commercially and clinically. The DEA has been explicit that its target is enhanced and synthetic 7-OH, not the botanical kratom leaf, and it set concentration thresholds precisely so the scheduling captures the concentrated products while leaving traditional low-potency kratom outside the order for now. The FDA, which had already begun warning about these products and calling them out by name, supported the move, and the agency’s framing captured the core deception: these were opioids hiding in plain sight, sold with the packaging and placement of wellness products to consumers who had no reason to read them as dangerous.
The Evidence That 7-OH Became a Public Health Problem
Any case for treating 7-OH as a genuine hazard rather than a moral panic rests on a harm signal that grew unmistakable as the products spread. At the Blue Ridge Poison Center at the University of Virginia, hospitalizations linked to kratom products rose from 43 in 2015 to 538 in 2025, a more than tenfold increase concentrated in the years the concentrated 7-OH products proliferated. Clinicians describe the severe cases in language that leaves little doubt about what they are dealing with: patients who took what they believed was a mild supplement and, especially in combination with other medications, ended up comatose and on life support.
Federal monitoring told the same story. In building its scheduling case, the DEA queried the FDA’s adverse-event database and found 7-OH reports climbing year over year, dominated by exactly the outcomes an opioid produces: drug dependence and withdrawal syndrome. Potency estimates that clinicians cite are striking, with poison-center physicians describing 7-OH as many times more potent than morphine. That is the profile of a serious opioid, and the fact that it was reaching consumers through gas stations and smoke shops rather than pharmacies or dealers is what gave the situation its particular shape, a genuinely new distribution channel for opioid dependence that the treatment system has not yet reckoned with.
Why a 7-OH Ban Becomes a Treatment Problem
Prohibition changes the legal status of a substance overnight, and the biology of dependence not at all, and this is where the scheduling becomes the addiction field’s problem. People who developed a physical dependence on concentrated 7-OH will not be freed of it by a Federal Register notice. When the products vanish from the shelf where they bought them, those users face the same choice any opioid-dependent person faces when the supply is cut: endure withdrawal, seek treatment, or find the drug somewhere else. Some will taper down and be fine. Some will arrive at clinics and emergency departments in withdrawal, and some, having learned that a familiar receptor answers to other opioids, will be pushed toward the illicit fentanyl supply that is far more likely to kill them.
That last possibility is the one that should sharpen providers’ attention, because it is the recurring pattern of American drug prohibition, that closing one supply without addressing the underlying dependence tends to divert demand rather than end it. The clinical task itself is manageable, since 7-OH dependence is opioid dependence and responds to the same evidence-based tools, the buprenorphine and methadone and supervised withdrawal that the field already knows, and its management runs into the same fragmented reimbursement and access barriers that constrain all of medication-based addiction treatment. But it requires that clinicians recognize the presentation, ask the right questions of patients who may not think of a supplement as a drug, and be ready for a population that does not fit the profile of a typical opioid patient and may not identify as one.
What the 7-OH Scheduling Means for Addiction Treatment Providers
For treatment operators, 7-OH is worth understanding now, in the window between the announcement and the ban taking full effect, because the demand it generates will not announce itself clearly. The action was still a proposal at the end of July, not yet a ban. The DEA filed its notices of intent on July 1 and published them on July 6, an HHS comment period on the proposed threshold ran through July 31, and by statute the temporary order cannot take effect before August 5, 2026, which means the supply disruption and the wave of people seeking help are imminent but had not yet arrived. Providers who understand the compound before their patients start presenting with it will be positioned to screen for it, to educate referral sources, and to meet a need that the people experiencing it may not know how to name.
A larger lesson sits at the intersection of commerce and regulation that this publication watches closely. 7-OH is a case study in how a lightly regulated supplement market can breed a genuine addiction problem in the open, sold legally and branded as wellness until the harm becomes undeniable and the government reaches for the bluntest tool it has. Scheduling will disrupt a market estimated in the hundreds of millions of dollars, push a dependent population toward a treatment system that does not yet expect it, and test once again whether prohibition without treatment capacity does more than move the problem. The addiction field has seen this sequence before, visible most recently as novel substances kept appearing in a drug supply that stays a step ahead of the last intervention. What is different this time is that the substance was sitting by the register, and the people it caught mostly thought they were buying something safe.
